AIM ImmunoTech Inc. (AMEX:AIM) is a biotechnology company focused on developing therapies for immune system disorders. On March 4, 2025, Equels Thomas K, the director, CEO, and President of AIM, purchased 83,334 shares of Common Stock at $0.12 each. This acquisition increased his total ownership to 1,764,029 shares, signaling confidence in the company's future.
The stock is currently priced at $0.1234, reflecting a 2.75% increase with a price change of $0.0033. It has fluctuated between $0.1128 and $0.1309 during the day. Over the past year, AIM's stock has seen a high of $0.62 and a low of $0.11, indicating significant volatility. The company's market capitalization is approximately $8.48 million, with a trading volume of 1,185,834 shares.
AIM has recently appointed David Chemerow as an Independent Director to its Board. With over 40 years of experience in finance, accounting, and operations, Mr. Chemerow's expertise is expected to benefit AIM. His previous roles include Chief Financial Officer and Treasurer, as well as Chief Revenue Officer at Comscore, Inc., and Chief Operating Officer and Chief Financial Officer of Rentrak Corporation.
The addition of Mr. Chemerow to the Board comes at a time when AIM is experiencing stock price fluctuations. His financial and operational leadership could provide stability and strategic direction. The unanimous decision by the Board to appoint him highlights the confidence in his ability to contribute positively to AIM's growth and development.
